Novo Nordisk has petitioned the U.S. FDA to prohibit compounding pharmacies from making generic versions of semaglutide, the active ingredient in its weight-loss and diabetes drugs, Ozempic and Wegovy. The company argues that the drug is too complex for safe compounding and should be added to the FDA’s Demonstrable Difficulties for Compounding Lists, which would block such practices regardless of drug shortages. This move comes amid shortages of these drugs in the U.S., leading many patients to turn to compounded versions, which are cheaper but have been found to contain impurities and incorrect dosages. Novo Nordisk, alongside Eli Lilly, has taken legal action against entities selling these unapproved versions, citing safety concerns. The FDA is currently reviewing Novo Nordisk's petition, and the outcome could significantly impact the availability and pricing of these medications, affecting millions who rely on them for obesity and diabetes treatment.